Compare Fox Corp Class A (FOXA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Recursion Pharmaceuticals Inc — how do they compare? Fox Corp Class A trades at $62.81 (market cap $24.58B), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Fox Corp Class A is far larger — about 13.6× Recursion Pharmaceuticals Inc's market cap, and Fox Corp Class A pays a 0.93% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| FOXA | RXRX | |
|---|---|---|
Market Cap | $24.58B | $1.81B |
Sector | Media | Health |
52-Week High | $76.11 | $6.79 |
52-Week Low | $48.79 | $2.84 |
Enterprise Value | $27.94B | $1.33B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $62.30, down 1.77% on the day, with a bullish technical signal and strong quarterly earnings beats. Recent Q2 2026 EPS of $1.79 exceeded the $1.44 estimate, driven by World Cup advertising and Tubi streaming growth. The stock shows robust fundamentals with a P/E of 16.18 and net income margin of 9.84%, supported by $3.32B in operating cash flow for 2025.
The outlook is positive with a $65.33 consensus price target and 50% analyst buy ratings, though risks include reliance on sports rights and projected 2026 net cash flow decline. Upside hinges on sustained ad demand and digital segment execution amid competitive pressures.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
